

SUPPLEMENTARY TABLE

Supplementary Table 3. Comparison of the expression of *TCOF1* between immunotherapy responders and non-responders.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log ₂ (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.03	0.921
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.196	0.908
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.101	0.943
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.142	0.605
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.088	0.972
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.215	0.948
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.31	0.384
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.103	0.947
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.568	0.739
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.451	0.714
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.645	0.722
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.015	0.829